Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NCK1
REST API REST API
Homo sapiens
NCK1 is differentially expressed in 308 experiments: 132 organism parts: bone marrow, kidney, ... (130 more);, 182 disease states: normal, Huntington's disease, ... (180 more);, 94 cell types 348 cell lines 47 compound treatments and 75 other conditions.
Synonyms NCK, NCKalpha
Orthologs NCK1 (2 of 2) (Danio rerio)   nck1 (Danio rerio)   Nck1 (Rattus norvegicus)   Nck1 (Mus musculus)   Q1LZB2_BOVIN (Bos taurus)   ENSCING00000007947 (Ciona intestinalis)   dock (Drosophila melanogaster)   nck1 (Xenopus laevis)   NCK1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term lamellipodium assembly, cytosol, cell migration, vesicle membrane, endoplasmic reticulum, protein binding, cytoplasm, signal complex assembly, regulation of translation, receptor binding, protein domain specific binding, actin filament organization, positive regulation of actin filament polymerization, axon guidance, receptor signaling complex scaffold activity, nucleus, cytoskeletal adaptor activity, T cell receptor signaling pathway, T cell activation, positive regulation of T cell proliferation
InterPro Term SH2, SH3_domain, Cytoplasmic_NCK, SH3_2
UniProt Accession P16333, C9J0K5, C9J869, C9JAB9, C9K098, B7Z751, C9JVV5
Search EB-eye ENSG00000158092
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-4717, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1937
2
E-MTAB-37, E-MTAB-62
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MOLT4
2
E-MTAB-62, E-MTAB-37
342 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (44 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-26672, E-GEOD-3204
stromal cell
2
E-MEXP-1121, E-GEOD-10797
adipocyte
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-TABM-145
macrophage
1
2
E-GEOD-8286, E-GEOD-22373, E-GEOD-3982
88 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-1577, E-MTAB-62, E-MTAB-680, E-GEOD-5418, ... (64 experiments)

Factor Value U/D Experiments
Huntington's disease
3
E-GEOD-1751, E-AFMX-6, E-GEOD-3790
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-GEOD-2514
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
176 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
5-fluorouridine
1
1
E-GEOD-995
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
hydroxyurea
1
E-GEOD-6431
heregulin
1
E-GEOD-6462
M-CSF
1
E-GEOD-5099
41 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
28
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-GEOD-17189, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-1751 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-TABM-321, E-TABM-868, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20504, ... (10 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-TABM-118, ... (37 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561, E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.29 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM